Human epidermal growth factor receptor-2 (HER2), estrogen receptor (ER), and progesterone receptor (PgR) are used to stratify breast cancer patients who respond to anti-HER2 antibody (trastuzumab) or hormone therapy. This evidence concerns the gene ERBB2 and breast carcinoma.